Conceivable Life Sciences, a NYC-based biotech company which specializes in fertility care, raised $18M in Series A funding.
The round was led by ARTIS Ventures with participation from new investors including Atlantic Health Venture Studio, Muse Capital, Scrub Capital, ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, and Time BioVentures.
The company intends to use the funds to support the ongoing commercial pilot program in Mexico City and preparations for U.S. launch timed for early 2026.
Led by CEO Alan Murray, Conceivable synthesizes AI and robotics to automate the more than 200 intricate steps required to create embryos for IVF, routinely performing delicate single cell surgery at the microscopic level. The company achieved the automated intracytoplasmic sperm injection (ICSI), successfully performed both onsite and remotely, spanning 3,000 miles between the reproductive cells within its system and the embryologist operator in New York.
Conceivable has raised over $39 million to date.
FinSMEs
15/01/2025